INNOGLY is the acronym of the COST Action CA18103: INNovation with GLYcans: new frontiers from synthesis to new biological targets.
The main aim of INNOGLY is to build up a multidisciplinary group of researchers to move forward new concepts, ideas and approaches to address glycan-related scientific challenges from new and wider perspectives. Specifically, the implementation of the Action rests on two pillars:
1) Glycan profiling in health and disease, where studies will be more specifically focused on glycan- based correlations in developmental and cancer biology, and glycan dependent modulation of autophagy in cancer, lysosomal disorders and neurodegenerative diseases.
2) Glycan-based diagnostics and therapeutics, where INNOGLY investigators will focus on glycan dependent fine tuning of immunity, and the exploration of the multifaceted roles of glycosaminoglycans.
GRANT HOLDER: Department of Chemistry ‘Ugo Schiff’, University of Firenze
Scientific Representative: Prof. Dr. Barbara Richichi
ACTION Chair: Prof Luigi LAY
ACTION Vice Chair: Jose Juan REINA MARTIN
WG1: Glycan-based correlations in developmental and cancer biology. Leader: Prof. Celso REIS
WG2: Glycan dependent modulation of autophagy, endocytosis and lysosomal functions: cancer, lysosomal disorders and neurodegenerative diseases. Leader: Eeva-Liisa ESKELINEN
WG3: Glycan dependent fine tuning of immunity. Leader: Prof Barbara RICHICHI
WG4: Exploring the multifaceted roles of glycosaminoglycans (GAGs). Leader: Dr. Serge PEREZ
Science communication Manager: Dr. Fabrizio CHIODO
STSM coordinator: Marko ANDERLUH